WH0008658M1
Monoclonal Anti-TNKS antibody produced in mouse
clone 1A2, purified immunoglobulin, buffered aqueous solution
别名:
Anti-PARP5A, Anti-PARP5a, Anti-PARPL, Anti-TIN1, Anti-TINF1, Anti-TNKS1, Anti-tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase
登录 查看组织和合同定价。
选择尺寸
关于此项目
Conjugate:
unconjugated
Clone:
1A2, monoclonal
Application:
immunohistochemistry (formalin-fixed, paraffin-embedded sections)
indirect ELISA
western blot
indirect ELISA
western blot
Species reactivity:
human
Citations:
6
Technique(s):
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
indirect ELISA: suitable
western blot: 1-5 μg/mL
indirect ELISA: suitable
western blot: 1-5 μg/mL
Uniprot accession no.:
产品名称
Monoclonal Anti-TNKS antibody produced in mouse, clone 1A2, purified immunoglobulin, buffered aqueous solution
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
1A2, monoclonal
form
buffered aqueous solution
species reactivity
human
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
indirect ELISA: suitable
western blot: 1-5 μg/mL
isotype
IgG2aκ
GenBank accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... TNKS(8658)
Biochem/physiol Actions
TNKS (tankyrase) is a regulator of Wnt-signaling. It negatively regulates Axin1, thereby suppressing β-catenin degradation and causing hyperactivation of Wnt/β-catenin signaling. TNKS controls cell death and telomere length. It might also be associated with osteoarthritis. In murine lung cancer model, silencing of this gene reduces lung cancer cell growth. Application of TNKS inhibitor suppresses growth of hepatocellular carcinoma cells. Absence of TNKS activity helps in replication of human cytomegalovirus (HCMV).
General description
The gene TNKS (tankyrase) is mapped to human chromosome 8p23.1. It belongs to the PARP (poly (ADP-ribose) polymerase) family of proteins and is responsible for addition of poly (ADP-ribose) (PAR) to substrate proteins. The TNKS protein contains ankyrin repeats and a sterile α-motif (SAM).
Immunogen
TNKS (NP_003738, 1017 a.a. ~ 1124 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Sequence
TERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEE
Sequence
TERKEGEVAGLDMNISQFLKSLGLEHLRDIFETEQITLDVLADMGHEELKEIGINAYGHRHKLIKGVERLLGGQQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEE
Physical form
Solution in phosphate buffered saline, pH 7.4
Legal Information
GenBank is a registered trademark of United States Department of Health and Human Services
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
法规信息
常规特殊物品
此项目有
Sujayita Roy et al.
Viruses, 8(1) (2016-01-06)
Human cytomegalovirus (HCMV) was reported to downregulate the Wnt/β-catenin pathway. Induction of Axin1, the negative regulator of the Wnt pathway, has been reported as an important mechanism for inhibition of β-catenin. Since Tankyrase (TNKS) negatively regulates Axin1, we investigated the
Genetic variants in eleven telomere-associated genes and the risk of incident cardio/cerebrovascular disease: The Women's Genome Health Study.
Zee RY, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 412, 199-202 (2011)
A genome-wide association study of copy-number variation identifies putative loci associated with osteoarthritis in Koreans.
Moon S, et al.
BMC Musculoskelet. Disord., 16, 76-76 (2015)
Tankyrase inhibitors attenuate WNT/?-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L, et al.
Oncotarget, 6, 25390-25401 (2015)
Sharon McGonigle et al.
Oncotarget, 6(38), 41307-41323 (2015-10-30)
Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment. Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持